• 1
    Valdes, R Jr. Endogenous digoxin-like immunoreactive factors: impact on measurements and potential physiologic implications. Clin Chem. 1985; 31: 152532.
  • 2
    Batzan S, Clerico A, Del Chicca MG, et al. Digoxin-like immunoreactivity in normal human plasma and urine as detected by a rapid-phase radioimmunoassay. Clin Chem. 1984; 30: 4501.
  • 3
    Klingmuller D, Weiler E, Kramer HJ. Digoxin-like natriuretic activity in the urine of salt loaded healthy subjects. Klin Wochenschr. 1982; 60: 124953.
  • 4
    Graves SW, Williams GH. Endogenous digitalis-like natriuretic factors. Annu Rev Med. 1987; 38: 43344.
  • 5
    Liu Z, Yao R, Yang D. Endogenous digoxin-like substance as an important factor in the development of hypertension in children. Int J Cardiol. 1990; 29: 3438.
  • 6
    Hamlyn JM. Ringel R., Schaeffer J. et al. A circulating inhibition of Na + K + -ATPase associated with essential hypertension. Nature. 1982; 300: 6503.
  • 7
    Goodlin RC. Antidigoxin antibodies in eclampsia. N Engl J Med. 1988; 318: 5189.
  • 8
    Kerkey SA, Poston L. Wolfe CD et al. A longitudinal study of maternal digoxinlike immunoreactive substances in nor-motensive pregnancy and pregnancy-induced hypertension. Am J Obstet Gynecol. 1990; 162: 7837.
  • 9
    Shilo L, Pomeranz A, Rathaus M, et al. Endogenous digoxin-like factor raises blood pressure and protects against digitalis toxicity. Life Sci. 1989; 44: 186770.
  • 10
    Stone J, Bentur Y. Zalstein E, et al. Effect of endogenous digoxin-like substances on the interpretation of high concentrations of digoxin in children. J Pediatr, 1990; 117: 3215.
  • 11
    Bentur Y, Singer P. Post-mortem digoxin-like immunoreactive substances (DLIS): are they present in patients not treated with digoxin? [Abstract], International Congress of Clinical Toxicology, 1993.
  • 12
    Hoffman BF, Bigger JT. Digitalis and allied cardiac glycosides. In: GilmanAG., GoodmanLS, GilmanA (eds). The Pharmacological Basis of Therapeutics, ed 6. New York: Macmillan Publishing. 1980, pp 72956.
  • 13
    Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol. 1992; 69(suppl): 97G107G.
  • 14
    Gruber KA, Whitaker JM, Buckalew VM. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature. 1980; 287: 7435.
  • 15
    Ebara H. Suzuki S, Nagashima K, et al. Digoxin-like immunoreactive substances in urine and serum from preterm and term infants: relationship to renal excretion of sodium. J Pediatr. 1986; 108: 7602.
  • 16
    Halpcrin JA, Riordan JF, Tosteson DC. Characteristic of an inhibitor of the Na + K + -ATPase pump in human cerebrospinal fluid. J Biol Chem. 1988; 263: 64651.
  • 17
    Hamlyn JM, Harris DW. Ludens JH. Digitalis-like activity in human plasma. J Biol Chem. 1989; 247: 7395404.
  • 18
    Seccombe DW. Pudek MR, Humphries KH. A study into the nature and organ source of digoxin-like immunoreactive substance(s) in the perinatal period. Biol Neonate. 1989; 56: 13646.
  • 19
    Shilo L, Shapiro MS, Dolev S, et al. Endogenous digoxin-like material is of adrenal origin. Isr J Med Sci. 1987; 23: 2945.
  • 20
    Pernollet MG, Ali RM, Meyer P, et al. Are the circulating digitalis-like substances of adrenal origin J Hypertens. 1986: 4(suppl 6): S382S384.
  • 21
    Takahashi H. Evidence of a digoxin-like substance in the hypothalmo-pituitary axis in rats. J Hypertens. 1986; 4(suppl 6): S317320.
  • 22
    Beyers AD, Spruyt LL, Seifart HI, et al. Endogenous immunoreactive digitalis-like substance in neonatal serum and placental extracts. S Afr Med J. 1984; 65: 87882.
  • 23
    Hnatowich M. Labella F. Endogenous digitalis-like factors: In vitro comparison of biological and immunological activities of peptides and steroid candidates. Eur J Pharmacol. 1984; 106: 56775.
  • 24
    Fagoo M, Braguet P. Robin JP, et al. Evidence that mammalian ligands show endogenous digitalis-like activities. Bio-phys Res Commun. 1986; 134: 106470.
  • 25
    Vasdev S. Longerich L., Johnson E, et al. Dehydroepiandrosterone sulfate as a digitalis-like factor in plasma of healthy human adults. Res Commun Clin Pathol Pharmacol. 1985; 49: 38799.
  • 26
    Kelly RA, OHara DS, Mitch WE, et al. Identification of Na + K+ -ATPase inhibitors in human plasma as nonesterified fatty acids and lysophospholipids. J Biol Chem. 1986; 261: 1170411.
  • 27
    Hamlyn J, Schienden J. Purification and characterization of digitalis-like factors from human plasma. Hypertension. 1987; 10(suppl I): I71I77.
  • 28
    Vasdev S. Longerich L, Ittel TH, et al. Bile salts as endogenous digitalis-like factors. Clin Invest Med. 1986; 9: 2018.
  • 29
    Toseland PA, Oldfield PR, Murphy GM, et al. Tentative identification of a digoxin-like immunoreactive substance. Ther Drug Monit. 1988; 10: 16871.
  • 30
    Ahmad S, Kenny M. Scribner BH. Hypertension and digoxin-like substances in the plasma of dialysis patients: possible markers for natriuretic hormone. Clin Physiol Biochem. 1986; 4: 2106.
  • 31
    Graves SW, Brown BA, Valdes, R Jr. Digoxin-like substance in patients with renal impairment. Ann Intern Med. 1983; 99: 6048.
  • 32
    Yang S, Korula J, Sunderheimer J. et al. Digoxin-like immunoreactive substances in chronic liver disease. 1989; 9: 3636.
  • 33
    Nanji AA, Greenway DC. Falsely raised plasma digoxin concentrations in liver disease. Br Med J. 1985; 287: 4323.
  • 34
    Nikou GC. Vyssoulis GP Venetikou MS et al. Digoxin-like substance(s) interfere(s) with serum estimations of the drug in cirrhotic patients. 1989; 11: 4303.
  • 35
    Shilo L, Adawi A, Solomon G, et al. Endogenous digoxin-like immunoreactivity in congestive heart failure. Br Med J. 1987: 295: 4156.
  • 36
    Graves SW. Valdes R Jr., Brown BA, et al. Endogenous digoxin-immunoreac-tive substance in human pregnancies. J Clin Endocrinol. Metabolism. 1984; 58: 74851.
  • 37
    Krivoy N, Jakobi P, Paidi E. et al. Total digoxin-like immunoreactive factor(s) in healthy population, uncomplicated pregnancies and neonates. J Endocrinol Invest. 1990; 13: 912.
  • 38
    Valdes R, Graves SW, Brown BA, et al. Endogenous substance in newborn infants causing false positive digoxin measurements. J Pediatr. 1983; 102: 947950.
  • 39
    Balzan S, Ghione S, Biver P, et al. Partial purification of endogenous digitalislike compound(s) in cord blood. Clin Chem. 1991; 37: 27781.
  • 40
    Wahyono D, Piechacyk M, Scherrmann JM. et al. Highly specific radioimmunoassay for digoxin using a monoclonal antibody selected for lack of interference by digoxin-like immunoreactive substances in cord blood sera. Ther Drug Monit. 1991: 13: 1139.
  • 41
    Lacerelle B, Durand A, Labadie N, et al. Comparison of digoxin-like immunoreactive substance cross-reactivity with two digoxin automated immunoassays. Ther Drug Monit. 1989; 11: 7256.
  • 42
    Valdes R Jr, Graves SW. Protein binding of endogenous digoxin immunoreactive factors in human serum and its variation with clinical condition. J Clin Endocrinol Metab. 1985; 60: 113543.
  • 43
    Karboski JA, Godley PJ, Frohna PA, et al. Marked digoxin-like immunoreactive factor interference with an enzyme immunoassay. Drug Intell Clin Pharm. 1988; 22: 7035.
  • 44
    Avendano C, Soto J, Sacristan A, et al. Interference of digoxin-like immunoreactive substances with TDx digoxin II assay in different patients. Ther Drug Monit. 1991; 13: 5237.
  • 45
    Kwong E, Embell L, McErlane KM. Comparison of analysis of digoxin in cardiac patients by HPLC and RIA. Res Commun Chem Pathol Pharmacol. 1990; 68: 1214.
  • 46
    Morris RG. Interference from digoxin-like immuno reactive substance(s) in commercial digoxin kit assay methods. Eur J Clin Pharmacol. 1990: 39:35963. 47. Ray JE, Crisan D, Howrie DL. Digoxin-like immunoreactivity in serum from neonates and infants reduced by centrifugal ultrafiltration and fluorescence polarization immunoassay. Clin Chem. 1991; 37: 94–8.